Moleculera Labs Collaborated with General Genomics to Offer Personalized Therapies for Autoimmune Neuropsychiatric Disorders Using AI
Shots:
- The collaboration will use GGI's ML & AI innovations to direct individualized healthcare via the Curo46 engine & Moleculera's expertise in autoimmune neuropsychiatric disorders along with patient data by using Moleculera Labs' AE/BGE or Cunningham Panel
- This blood test measures the levels of Abs that target the brain and CNS & are linked to neurologic, psychiatric & behavioral diseases. General Genomics uses a variety of data sources with its AI expertise to determine a person's risk for illness, disease & the probability of treatment success, effective & free of side effects
- This collaboration will give superior precision medicine tools for treating neuropsychiatric diseases, minimizing the need for trial and error
Ref: PRNewswire | Image: Moleculera Labs
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
